- Conditions
- Tuberculosis
- Interventions
- BCG strain Connaught, BCG strain Danish, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 154
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bladder Cancer
- Interventions
- Bacille Calmette-Guerrin (BCG), Lenalidomide
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- Erdafitinib Intravesical Delivery System
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more
- Conditions
- Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
- Interventions
- Intravesical Gemcitabine and Docetaxel
- Drug
- Lead sponsor
- Michael A. O'Donnell
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Bladder Cancer
- Interventions
- ADSTILADRIN
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 31
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 25 more
- Conditions
- High-risk Non-muscle Invasive Bladder Cancer
- Interventions
- Pembrolizumab, BCG
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2034
- U.S. locations
- 44
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more
- Conditions
- Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Dallas, Texas
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- inodiftagene vixteplasmid
- Drug
- Lead sponsor
- Anchiano Therapeutics Israel Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 48
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more
- Conditions
- Urothelial Carcinoma Bladder, Bladder Cancer
- Interventions
- Gemcitabine, Docetaxel
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer
- Interventions
- BCG vaccine, CD80 breast cancer vaccine, sargramostim
- Biological
- Lead sponsor
- Providence Cancer Center, Earle A. Chiles Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Bladder Cancer
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
- Interventions
- EN3348, Mitomycin C
- Biological
- Lead sponsor
- Bioniche Life Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 56
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
- Conditions
- Tuberculosis
- Interventions
- AERAS-422, BCG Tice
- Drug
- Lead sponsor
- Aeras
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes
- Interventions
- Bacillus Calmette-Guérin, Saline Injection
- Biological
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- TAR-200, Mitomycin C, Gemcitabine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 29
- States / cities
- Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 24 more
- Conditions
- Bladder Cancer
- Interventions
- Everolimus and Intravesical Gemcitabine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- nivolumab, Placebo, Bacillus Calmette-Guérin (BCG)
- Drug · Other · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • The Bronx, New York
- Conditions
- Bladder Cancer
- Interventions
- BCG vaccine, recombinant interferon alfa
- Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
- Interventions
- BCG Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 659 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Bryan, Texas • Houston, Texas
- Conditions
- Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer, Bladder Cancer
- Interventions
- Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
- Drug · Other
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 27
- States / cities
- Gilbert, Arizona • Bakersfield, California • Los Angeles, California + 24 more
- Conditions
- Non-Muscle- Invasive Bladder Cancer
- Interventions
- Durvalumab, BCG
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Urinary Bladder, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- UGN-501
- Biological
- Lead sponsor
- UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Queen Creek, Arizona • Bakersfield, California • Murrieta, California + 12 more
- Conditions
- Non Muscle Invasive Bladder Cancer
- Interventions
- CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
- Biological · Other
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 13
- States / cities
- La Jolla, California • Orange, California • Tampa, Florida + 9 more
- Conditions
- High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure, Transitional Epithelial Cells
- Interventions
- MK-3475 and BCG
- Drug
- Lead sponsor
- Shaheen Alanee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Detroit, Michigan